| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| 500mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
IDE1 targets the TGF-β signaling pathway. It activates SMAD2 phosphorylation and upregulates NODAL expression. By activating this pathway, IDE1 induces the differentiation of pluripotent stem cells into definitive endoderm. It has an EC50 of 125 nM for inducing definitive endoderm formation. It induces the differentiation of Sox17+/FoxA2+-expressing pancreatic progenitors.
|
|---|---|
| ln Vitro |
Human induced pluripotent stem cells (hiPSCs) secrete more definitive endoderm (DE) when IDE1 is present. In 2D and 3D cultures, activin A/Wnt3a was found to be substantially more potent than IDE1. IDE1 can effectively induce DE by a variety of in vitro procedures. When IDE-1 was used to treat hiPSC-derived EBs, there was a somewhat higher number of DE-labeled cells than when Activin A/Wnt3a was used (p<0.01). IDE1 is superior to other inducers in a number of ways, including high permeability, influence, diversity, and user-friendliness. Melton's group demonstrated for the first time that two tiny molecules, IDE1 and IDE2, that are permeable to cells, can take the place of activin A. In the sidewall, IDE1 can cause Smad2 phosphorylation at least 24 hours later and at amounts similar to those brought on by activin A therapy. While endoderm rupture is caused by IDE1 (2 mM) treatment of hiPSCs, the efficiency is much lower than that of Activin A/Wnt3a[1].
IDE1 induces definitive endoderm formation with an EC50 of 125 nM. It activates SMAD2 phosphorylation and upregulates NODAL expression. It induces the differentiation of Sox17+/FoxA2+-expressing pancreatic progenitors. Its activity has been confirmed in various in vitro assays using mouse and human embryonic stem cells. |
| ln Vivo |
IDE1 has been shown to induce definitive endoderm formation in both mouse and human embryonic stem cells. It enhances the definitive endoderm differentiation of human-induced pluripotent stem cells (hiPSCs). Its ability to direct endodermal differentiation makes it a valuable tool for studying developmental biology and for generating cells for regenerative medicine.
|
| Enzyme Assay |
The primary in vitro assay for IDE1 involves measuring its ability to induce definitive endoderm differentiation in embryonic stem cells or induced pluripotent stem cells. Cells are treated with the compound, and the expression of definitive endoderm markers, such as Sox17 and FoxA2, is measured by qPCR or immunostaining. The EC50 of 125 nM is determined from dose-response curves.
|
| Cell Assay |
In vitro cellular experiments for IDE1 involve treating pluripotent stem cells with the compound and measuring its effects on differentiation. The expression of definitive endoderm markers, such as Sox17, FoxA2, and CXCR4, is assessed by qPCR, immunostaining, or flow cytometry. The activation of SMAD2 phosphorylation is assessed by Western blot. The differentiation into pancreatic progenitors can be assessed by measuring the expression of PDX1 and other markers.
|
| Animal Protocol |
In vivo animal experiments for IDE1 are not extensively detailed in the available literature. As a small molecule that induces endoderm differentiation, it could be evaluated in animal models for its ability to generate endodermal tissues or to treat diseases affecting endoderm-derived organs. Its effects on stem cell differentiation and tissue regeneration would be assessed.
|
| ADME/Pharmacokinetics |
IDE1 has a molecular weight of 312.36 g/mol and a molecular formula of C18H16N2O3. It is a cell-permeable small molecule. It is soluble in DMSO. It is typically used as a research reagent and is stored as a powder at -20°C for long-term stability. Its purity is typically ≥98%.
|
| Toxicity/Toxicokinetics |
IDE1 is a research compound that is not intended for human use. Its toxicological profile is not extensively characterized in the available literature. As with all research chemicals, standard safety precautions should be followed when handling. Its safety would need to be established for therapeutic applications.
|
| References | |
| Additional Infomation |
IDE1 is a novel, potent, and cell-permeable small molecule that induces definitive endoderm formation from embryonic stem cells with an EC50 of 125 nM. It activates the TGF-β signaling pathway by inducing SMAD2 phosphorylation and NODAL expression. IDE1 is used in research on stem cell differentiation and developmental biology.
|
| Molecular Formula |
C15H18N2O5
|
|---|---|
| Molecular Weight |
306.313824176788
|
| Exact Mass |
306.121
|
| CAS # |
1160927-48-9
|
| PubChem CID |
23749403
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Index of Refraction |
1.572
|
| LogP |
1.66
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
22
|
| Complexity |
422
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C(C(=C1)/C=N/NC(=O)CCCCCC(=O)O)C(=O)O
|
| InChi Key |
ABKJCDILEUEJSH-MHWRWJLKSA-N
|
| InChi Code |
InChI=1S/C15H18N2O5/c18-13(8-2-1-3-9-14(19)20)17-16-10-11-6-4-5-7-12(11)15(21)22/h4-7,10H,1-3,8-9H2,(H,17,18)(H,19,20)(H,21,22)/b16-10+
|
| Chemical Name |
7-[2-(2-Carboxybenzylidene)hydrazinyl]-7-oxoheptanoic acid
|
| Synonyms |
IDE1 IDE-1 IDE 1.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 30 mg/mL (~97.94 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.16 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.16 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.16 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2647 mL | 16.3233 mL | 32.6467 mL | |
| 5 mM | 0.6529 mL | 3.2647 mL | 6.5293 mL | |
| 10 mM | 0.3265 mL | 1.6323 mL | 3.2647 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA